See more : Semper Paratus Acquisition Corporation (LGSTU) Income Statement Analysis – Financial Results
Complete financial analysis of Bioxytran, Inc. (BIXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bioxytran, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lucky Friday Extn Mining Co. (LFEX) Income Statement Analysis – Financial Results
- Rico Auto Industries Limited (RICOAUTO.NS) Income Statement Analysis – Financial Results
- Amazon.com, Inc. (AMZN.NE) Income Statement Analysis – Financial Results
- European Healthcare Acquisition & Growth Company B.V. (EHCS.AS) Income Statement Analysis – Financial Results
- Jiangsu Lianyungang Port Co., Ltd. (601008.SS) Income Statement Analysis – Financial Results
Bioxytran, Inc. (BIXT)
About Bioxytran, Inc.
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 191.08K | 246.50K | 255.82K | 275.62K | 417.34K | 312.90K | 76.30K | 16.13K | 0.00 | 0.00 |
| Cost of Revenue | 8.29K | 3.64K | 0.00 | 0.00 | 0.00 | 0.00 | 103.98K | 96.30K | 135.69K | 165.98K | 197.39K | 121.92K | 19.07K | 4.03K | 0.00 | 0.00 |
| Gross Profit | -8.29K | -3.64K | 0.00 | 0.00 | 0.00 | 0.00 | 87.10K | 150.19K | 120.14K | 109.64K | 219.95K | 190.98K | 57.22K | 12.10K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45.58% | 60.93% | 46.96% | 39.78% | 52.70% | 61.04% | 75.00% | 74.99% | 0.00% | 0.00% |
| Research & Development | 1.15M | 977.77K | 2.01M | 544.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.47M | 1.16M | 2.20M | 724.18K | 1.63M | 214.71K | 397.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 197.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.67M | 1.16M | 2.20M | 724.18K | 1.63M | 214.71K | 397.69K | 821.47K | 2.21M | 1.39M | 2.19M | 2.48M | 2.41M | 341.13K | 272.15K | 24.22K |
| Other Expenses | 0.00 | 3.64K | 582.86K | 247.87M | 1.12B | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | -348.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| Operating Expenses | 3.82M | 2.14M | 4.21M | 1.27M | 1.63M | 214.71K | 397.69K | 821.47K | 2.21M | 1.39M | 2.19M | 2.48M | 2.41M | 341.13K | 272.15K | 24.22K |
| Cost & Expenses | 3.82M | 2.14M | 4.21M | 1.27M | 1.63M | 214.71K | 501.66K | 917.77K | 2.35M | 1.56M | 2.39M | 2.60M | 2.43M | 345.17K | 272.15K | 24.22K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.05K | 925.00 | 919.00 | 0.00 |
| Interest Expense | 541.83K | 519.55K | 313.61K | 1.27M | 227.01K | 8.38K | 7.80K | 7.80K | 7.80K | 7.80K | 12.66K | 3.55K | 4.40K | 8.36K | 5.12K | 109.00 |
| Depreciation & Amortization | 8.29K | 3.64K | 4.21M | 1.27M | 1.63M | 215.11K | 17.54K | 27.63K | 54.78K | 58.19K | 51.06K | 40.64K | 30.66K | 3.41K | 919.00 | 0.00 |
| EBITDA | -3.82M | -2.13M | -4.21M | -1.27M | -1.63M | 0.00 | -310.59K | -661.33K | -2.04M | -1.28M | -1.71M | -2.25M | -4.40M | -324.70K | -271.23K | -24.22K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -153.37% | -261.12% | -796.47% | -443.56% | -460.40% | -718.78% | -3,045.24% | -2,012.75% | 0.00% | 0.00% |
| Operating Income | -3.82M | -2.13M | -4.21M | -1.27M | -1.63M | -214.71K | -310.59K | -671.28K | -2.09M | -1.28M | -1.97M | -2.29M | -2.35M | -329.03K | -272.15K | -24.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -162.55% | -272.33% | -817.88% | -464.67% | -472.64% | -731.76% | -3,085.42% | -2,039.63% | 0.00% | 0.00% |
| Total Other Income/Expenses | -550.11K | -523.19K | -313.61K | -1.27M | -227.01K | -81.31K | -7.80K | -25.48K | -7.80K | -66.20K | 193.94K | -3.55K | -4.40K | -7.44K | -4.20K | 0.00 |
| Income Before Tax | -4.37M | -2.66M | -4.53M | -2.54M | -1.86M | -296.02K | -318.39K | -696.76K | -2.10M | -1.35M | -1.78M | -2.29M | -2.36M | -336.47K | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -166.63% | -282.67% | -820.93% | -488.69% | -426.16% | -732.90% | -3,091.18% | -2,085.73% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -193.37K | -182.69K | 1.21M | 227.01K | 400.00 | 7.80K | 25.48K | 7.80K | 66.20K | -193.94K | 3.55K | 4.40K | 7.44K | -919.00 | 24.32K |
| Net Income | -4.28M | -2.46M | -4.35M | -3.75M | -2.09M | -296.42K | -318.39K | -696.76K | -2.10M | -1.35M | -1.78M | -2.29M | -2.36M | -336.47K | -276.35K | -24.32K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -166.63% | -282.67% | -820.93% | -488.69% | -426.16% | -732.90% | -3,091.18% | -2,085.73% | 0.00% | 0.00% |
| EPS | -0.03 | -0.02 | -0.04 | -0.04 | -0.02 | 0.00 | -0.24 | -0.79 | -6.25 | -9.07 | -14.23 | -26.08 | -50.25 | -55.99 | -32.36 | -2.85 |
| EPS Diluted | -0.03 | -0.02 | -0.04 | -0.04 | -0.02 | 0.00 | -0.24 | -0.79 | -6.25 | -9.07 | -14.23 | -26.08 | -50.25 | -55.99 | -32.36 | -2.85 |
| Weighted Avg Shares Out | 134.22M | 115.14M | 106.25M | 93.97M | 85.60M | 85.10M | 1.32M | 883.50K | 336.07K | 148.43K | 125.02K | 87.94K | 46.93K | 6.01K | 8.54K | 8.54K |
| Weighted Avg Shares Out (Dil) | 134.22M | 115.14M | 106.25M | 93.97M | 85.60M | 85.10M | 1.32M | 883.50K | 336.07K | 148.43K | 125.02K | 87.94K | 46.93K | 6.01K | 8.54K | 8.54K |
Bioxytran's Medical Breakthrough in Fighting All Viruses
Breakthrough was validated in the latest journal article Galectins are essential for viral entry and a new target for drug development Carbohydrates were shown to neutralize viruses Blocking galectins could be the most efficient way to prevent and treat viruses...
Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier
The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat...
Bioxytran's Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer's Patients
BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced that Bioxtran's Science Advisor Prof.
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral...
Bioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT ), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced...
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other...
Bioxytran Interview at the Emerging Growth Conference
BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announced that Bioxtran CCO Michael Sheikh will be...
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that its preprint article titled “Evaluation of Complex Carbohydrates Showing Broad-Spectrum...
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that it has received clearance of its Investigational New Drug (IND)...
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced the initiation of a clinical trial to treat Mild to Moderate...
Source: https://incomestatements.info
Category: Stock Reports